Revance's Botox rival turned away by FDA after inspectors flagged manufacturing 'deficiencies'

Despite a pandemic delay and an FDA warning about quality control and record-keeping problems at a production site, Revance insisted it was optimistic the agency would approve its would-be Botox rival as recently as last week. Turns out the FDA had other plans.